Neuroinflammation and ageing: Current theories and an overview of the data

Reviews on Recent Clinical Trials

Volumn 6, Issue 3, 2011, Pages 189-203

  Pizza, Vincenzo ^a   Agresta, Anella ^a   D'Acunto, Cosimo W ^a   Festa, Michela ^b   Capasso, Anna ^b  

^a S Luca Hospital   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

Aging; Disease; Neuroinflammaging

Indexed keywords

MITOCHONDRIAL DNA;

AGING; ALZHEIMER DISEASE; ATHEROSCLEROSIS; CHRONIC INFLAMMATION; DNA POLYMORPHISM; GENE CONTROL; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; LIFESPAN; LIFESTYLE; LONGEVITY; NEOPLASM; NEURITIS; PRIORITY JOURNAL; REVIEW; SOCIETY; THEORY;

AGING; ALZHEIMER DISEASE; APOPTOSIS; ATHEROSCLEROSIS; BIOLOGICAL EVOLUTION; BRAIN; CELL AGING; CYTOKINES; DEHYDROEPIANDROSTERONE; ENVIRONMENT; FREE RADICALS; GROWTH HORMONE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMUNITY, INNATE; INFLAMMATION; LIFE STYLE; MELATONIN; NEOPLASMS; OXIDATIVE STRESS; PITUITARY-ADRENAL SYSTEM; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTES; TELOMERE; THYMUS GLAND;

EID: 80051707096     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/157488711796575577     Document Type: Review

References (123)

1. Wachter KW, Finch CE. Between Zeus and the Salmon. Washington: National Academ Press 1997.
2. Weinert BT, Timiras PS. Theories of Aging. J Appl Physiol 2003; 95:1706-16.
3. Kowald A, Kirkwood TB. A network theory of ageing: the interactions of defective mitochondria, aberrant proteins, free radicals and scavengers in the ageing process. Mutat Res 1996; 316: 209-236.
4. Migliaccio E, Giorgio M, Mele S, et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999; 402: 309-313.
5. Puca AA, Daly MJ, Brewster SJ, Matite TC, Barrett J, Shea- Drinkwater M, A genome-wide scan for linkage to human exceptional longevity identifies a locus on chromosome 4. Proc Natl Acad Sci USA 2001; 98: 10505-8.
6. Hayflick L, The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37: 614-36.
7. Campisi J, Cellular senescence and cell death. In: Timiras PS. Third ed. Physiological Basis of Aging and Geriatrics. Boca Raton: CRC Press 2003; 47-59.
8. Blackburn EH. Telomere states and cell fates. Nature 2000; 408: 53-6.
9. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
10. Reddel RR. The role of senescence and immortalization in carcino- genesis. Carcinogens 2000; 21: 477-484.
11. Ferrara N, Gorbi G, Scarpa D, Rengo G, Longobardi G. Teorie dell'invecchiamento. The aging theories. G Gerontol 2005; 53; 57-74.
12. Smith RG, Betancourt, L, Sun Y. Molecular endocrinology and physiology of the aging central nervous system. Endocr Rev 2005; 26: 203-50.
13. Bernard C. Leçons sur les phénomènes de la vie communsaux animaux et aux végétaux. Paris: JB Bailliere: 1878-79.
14. Cannon WB. The Wisdom of the Body. New York: WW Norton & Co 1932.
15. McEwen BS. The end of stress as we know it. Washington: Joseph Henry Press 2002.
16. Selye H. The Stress of Life. New York: McGraw-Hill 1976.
17. Nawata H, Yanase T, Goto K, et al. Adrenopause. Horm Res 2004; 62: 110-114.
18. Graham D, MCLachlan A. Declining melatonin levels and older people. How old is old? Neuro Endocrinol Lett 2004; 25: 415-418.
19. Arendt J. Melatonin. Clin Endocrinol 1988; 29: 205-229.
20. Armstrong SM, Redman JR, Melatonin: a chronobiotic with antiaging properties? Med Hypotheses 1991; 34: 300-309.
21. Bondy SC, Shaman EH. Melatonin and the aging brain. Neurochem Intern 2007; 50: 571-580.
22. Pierpaoli W, Regelson W. Pineal control of aging. Effects of melatonin and pineal grafting in aging mice. Proc Natl Acad Sci USA 1994; 91: 787-791.
23. Karasek M, Melatonin, human aging, and age-related diseases. Experimental Gerontology 2004; 39; 1723-1729.
24. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323: 1-6.
25. Nass R, Park J, Thorner MO. Growth hormone supplementation in the elderly. Endocrinol Metab Clin N Am 2007; 36: 233-245.
26. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 2647-2653.
27. Stoll BA. Dietary supplements of dehydroepiandrosterone in relation to breast cancer. Eur J Clin Nutr 1999; 53: 771-775.
28. Effros RB. From Hayflick to Walford: the role of T cell replicative senescence in human aging. Exp Gerontol 2004; 39: 885-890.
29. Gerli R, Paganelli R, Cossarizza A, et al. Long immunologic effects in thymectomy in patients with myasthenia gravis. Clin Immunol 1999; 103: 865-872.
30. Effros RB. Ageing and the immune system. Review. Novartis Found Symp 2001; 235: 130-9; discussion 139-45, 146-9.
31. Fagnoni FF, Vescovili R, Mazzola M, Bologna G, Nigro E. Expansion of cytotoxic CD8+ CD28+ T cells in healthy aged people and centenarians. Immunology 1996; 88: 501-517.
32. Timm JA, Thoman ML. Maturation of CD4+ lymphocytes in the aged microenvironment results in a memory-enriched population. J Immunol 1999; 162: 711-717.
33. Effros RB. Long-term immunological memory against viruses. Review. Mech Ageing Dev 2000; 121:161-71.
34. Wikby A, Johansson B, Olsson J, Lofgren, S, Nilsson BO, Ferguson F. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with citomegalovirus seropositivity in the elderly: the Swedish NONA immunestudy. Exp Gerontol 2002; 37: 45-53.
35. Pawelec G, Ouyang Q, Wikby A. Pathways to a robust immuneresponse in the elderly. Immunology and Allergy Clinics of North America: Impact of Immune Senescence on Human Aging. vol. 23. Philadelphia: WB Saunders Co 2003; 1-13.
36. Bonafè M, Valensin S, Gianni W, Marigliano V, Franceschi C. The unexpected contribution of immunosenescence to the levelling off of cancer incidence and mortality in the oldest old. Crit Rev Oncol Hematol 2001; 39: 227-233.
37. Pahlavani MA. T cell signaling: effect of age. Review. Front Biosci 1998; 3: 1120-1133.
38. Franceschi C, Monti D, Sansoni P, Cossarizza A, The immunology of exceptional inividuals: the lesson of centenarians. Immunol Today 1995; 16: 12-6.
39. Sansoni P, Cossarizza A, Brianti V, Fagnoni F, Snelli G. Lymphocytes subsets and natural killer cell activity in healthy old people and centenarians. Blood 1993; 82: 2767-2773.
40. Franceschi C, Monti D, Barbieri D, Grasselli E, Troiano L, Immunosenescence in umans: deterioration or remodelling? Intern Rev Immunol 1995; 2: 57-74.
41. Ogata K, Yokose N, Tamura H, An E, Nakamura K. Natural killer cells in the late decades of human life. Clin Immunol Immunopathol 1997; 84: 269-75.
42. Remarque E, Pawelec P, T cell immunosenescence and its clinical relevance in man. Rev Clin Gerontol 1998; 8: 5-14.
43. Kourilsky P, Truffa-Bachi P, Cytokine fields and the polarization of the immune response. Trends Immunol 2001; 22: 502-9.
44. Forsey RJ, Thompson JM, Ernerudh J, et al. Plasma citokine profiles in elderly humans. Mech Ageing Dev 2003; 12: 487-493.
45. Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M. Inflamm- aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000; 908: 8-18.
46. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257.
47. Akbar AN, Salmon M. Cellular environments and apoptosis: tissue microenvironmets control activated T-cell death. Immunol Today 1997; 18:72-76.
48. Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 407: 789-795.
49. Gupta S. Molecular steps of death receptor and mitocondrial pathways of apoptosis. Life Sci 2000; 69: 2957-2964.
50. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776.
51. Jaattela M, Tschopp J, Caspase-independent cell death in T lymphocytes. Nat Immunol 2003; 4: 416-423.
52. Franceschi C, Valensin S, Bonafè M, Prolisso G, Yashin A. The network and the remodelling theories of aging: historical background and new perspectives. Exp Gerontol 2000; 35: 887-896.
53. De Martinis M, Franceschi C, Monti D, Ginaldi L. Apoptosis remodelling in immunosenescence: implications for strategies to delay ageing. Curr Med Chem 2007; 14: 1389-1397.
54. Franceschi C, Bonafè M, Valensin S. Human immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space. Vaccine 2000; 18: 1717-1720.
55. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408: 239-247.
56. Franceschi C. Cell proliferation and cell death in the aging process. Aging Clin Exp Res 1989; 1: 3-1
57. Franceschi C, Ottaviani E. Stress, inflammation and natural immunity in the aging process: a new theory. Aging 1997; 9: 30-31.
58. Salvioli S, Capri M, Valensin S, et al. Inflamm-Aging, Cytokines and Aging: State of the Art, New Hypotheses on the Role of Mitochondria and New Perspectives from Systems Biology. Curr Pharm Design 2006; 12: 3161-3171.
59. De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett 2005; 579: 2035-2039.
60. Fagiola U, Cossarizza A, Scala E, et al. Increased cytokine production in mononuclear cells o healthy elderly people. Eur J Immunol 1993; 23: 2375-2378.
61. Franceschi C, Monti D, Sansoni P, Cossarizza A. The immunology of exceptional individuals:the lesson of centenarians. Immunol Today 1995; 16: 2-16.
62. Lio D, Scola L, Crivello A, et al. Inflammation, genetics, and longevity: further studies on the protective effects in men of IL-10 - 1082 promoter SNP and its interaction with TNF- -308 promoter SNP. J Med Genet 2003; 40: 296-299.
63. Candore G, Colonna-Romano G, Balestrieri CR, et al. Biology of longevity: role of the innate immune system. Rejuenation Res 2006; 9: 143-148.
64. Giunta S. Is inflammaging an auto [innate]immunity subclinical syndrome? Immun Ageing 2006; 3: 12.
65. Franceschi C, Motta L, Valensin S, Rapisarda R, Franzone A. Do men and women follow different trajectories to reach extreme longevity. Aging Clin Exp Res 2000; 12: 77-84.
66. Ginaldi L, De Martinis M, Monti D, Franceschi C. The immune system in the elderly: activation-induced and damage-induced apoptosis. Immunol Res 2004; 30: 81-94.
67. Bonafè M, Olivieri F, Cavallone L, et al. A 170 gender--dependent genetic predisposition to produce high levels of IL-6 is detrimental for longevity. Eur J Immunol 2001; 31: 2357-2361.
68. Salvioli S, Capri M, Valensin S, et al. Inflamm-aging, cytokines and aging: state of the art, new hypotheses on the role of mitochondria and new perspectives from systems biology. Curr Pharm Des 2006; 12: 3161-3167
69. Capri M, Salvioli S, Sevini F, et al. The genetics of human longevity. Ann N Y Acad Sci 2006; 1067: 252-263.
70. Franceschi C, Bezrukov V, Blanché H, et al. Genetics of healthy aging in Europe: the EU-integrated project GEHA (Genetics of Healthy Aging). Ann NY Acad Sci, 2007; 1100: 21-45.
71. Khan N, Shariff N, Cobbold M, et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002; 169: 1984-1992.
72. Ouyang Q, Wagner WM, Walter S, et al. The age-related increase in CD8+ T cells carrying receptors for an immunodominant Epstein- Barr virus (EBV) epitope is counterbalanced by decreased antigen- specific responsiveness. Mech Ageing Dev 2003; 124: 477-485.
73. Pawelec G, Akbar A, Caruso C, Solana R, Grubeck-Loebenstein B, Wikby A, Human immunosenescence: is it infectious? Immunol Rev. 2005; 205: 257-268.
74. Vescovili R, Telera A, Fagnoni FF, et al. Different contribution of EBV and CMV infections in very long-term carriers to age-related alterations of CD8+ T cells. Exp Gerontol 2004; 39: 233-1243.
75. Bürkle A, Caselli G, Franceschi C, et al. Pathophysiology of ageing, longevity and age related diseases. Immun Ageing 2007; 4: 4.
76. Kammerman EM, Neumann DM, Ball MJ, Lukiw W, Hill JM, Senile plaques in Alzheimer's diseased brains: possible association of beta-amyloid with herpes simplex virus type 1 (HSV-1) Lparticles. Med Hypotheses 2006; 66: 294-9.
77. Itzhaki R, Herpes simplex virus type 1, apolipoprotein E and Alzheimer' disease. Herpes 2004; 11: 77A-82A.
78. Letenneur L, Peres K, Fleury H, Garrigue I, Barberger-Gateau P, Helmer C, Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: a population-based cohort study. PLoS ONE 2008; 3: 36-37.
79. Ginaldi L, De Martinis M, Monti D, Franceschi C. The immune system in the elderly: activation-induced and damage-induced apoptosis. Immunol Res 2004; 30: 81-94.
80. Cesari M, Penninx BW, Pahor M, Inflammatory markers and physical performance in older persons: the INCHIANTI study. J Gerontol A Biol Sci Med Sci 2004; 59: 242-8.
81. Rowshani AT, Bemelman FJ, van Leeuwen EM, van Lier RA, ten Berge IJ, Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation 2005; 79: 381-386.
82. Salvioli S, Olivieri F, Marchigiani F, et al. Genes, ageing and longevity in humans: problems, advantages and perspectives. Free Radic Res 2006; 40: 1303-1323.
83. Carrieri G, Marzi E, Olivieri F, et al. The G/C915 polymorphism of transforming growth factor beta1 is associated with human longevity: a study in Italian centenarians. Agin Cell 2004; 3: 443-448.
84. Caruso C, Lio D, Cavallone L, Franceschi C. Aging, longevity, inflammation, and cancer. Ann N Y Acad Sci 2004; 1028: 1-13.
85. Franceschi C, Capri M, Monti D, et al. Inflammaging and antiinflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007; 128: 92-105.
86. Pawelec G, Akbar A, Caruso C, Solana R, Grubeck-Loebenstein B, Wikby A, Human immunosenescence: is it infectious? Immunol Rev 2005; 205: 257-268.
87. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK, Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003; 8: 541-552.
88. Serrano M, Blasco MA, Cancer and ageing: convergent and divergent mechanisms. Nat Rev Mol Cell Biol 2007; 8: 715-722.
89. Finkel T, Serrano M, Blasco MA, The common biology of cancer and ageing. Nature 2007; 448: 67-74.
90. Derhovanessian E, Solana R, Larbi A, Pawelec G. Immunity, ageing and cancer. Immun Ageing 2008; 5: 11.
91. Thun MJ, Henley SJ, Gansler T, Inflammation and cancer: an epidemiological perspective. Novartis Found Synp 2004; 256: 2-21.
92. Macarthur M, Hold GL, El-Omar EM. Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastointest Liver Physiol 2004; 286: G515-20.
93. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ, C-reactive protein and the risk of incident colorectal cancer. JAMA 2004; 291: 585-590
94. Hussain SP, Hofseth LJ, Harris CC, Radical causes of cancer. Nature Rev Cancer 2003; 3: 276-285.
95. Szlosarek PW, Balkwill FR, Tumor necrosis factor alpha: a potential target for the therapy of solid tumors. Lancet Oncol 2003; 4: 565-573.
96. Franceschi C. Un fuoco maligno. Le Scienze 2007; 82-89.
97. Ross R, Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
98. Goate A, Charter-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-706.
99. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's diseae. Nature 1995; 375: 754-760.
100. Rogaev EI, Sherrington R, Rogava EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995; 376: 775-778.
101. Solerte SB, Fioravanti M, Pascale A, Increased natural killer cell cytotoxicity in Alzheimer's disease may involve protein kinase C dysregulation. Neurobiol Aging 1998; 19: 191-199.
102. Solerte SB, Fioravanti M, Vignati G, Dehydroepiandrosterone sulfate enhances natural killer cell cytotoxicity in humans via locally generated immunoreactive insulin-lie growth factor I. J Clin Endocrinol Metabol 1999; 84: 3260-3267.
103. Licastro F, Pedrini S, Caputo L, et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol 2000; 103: 97-102.
104. Licastro F, Pedrini, S, Ferri C, et al. Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann Neurol 2000; 48: 388-391.
105. De Luigi A, Fragiacomo C, Lucca U, Quadri P, Tettamanti M, Grazia De Simoni M. Inflammatory markers in Alzheimer's disease and multi-infarct dementia. Mech Ageing Dev 2001: 122: 1985-1995.
106. Licastro, F, Chiappelli M. Brain immune responses cognitive decline and dementia: relationship with phenotype expression and genetic background. Mech Ageing Dev 2003; 124: 525-528.
107. Mukherjee P, Pasinetti GM. The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer's disease. J Neuroimmunol 2000; 105: 124-130.
108. Tan J, Town T, Paris D, Microglial activation resulting from CD40-CD40L interaction after beta amyloid stiulation. Science 1999; 286: 2352-2355.
109. Symposium: The role of inflammation in Alzheimer's disease. Neurobiol Aging 2000; 21: S285-S286.
110. Pasinetti GM, Aisen PS, Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998; 87: 319-324.
111. Ho L, Pieroni C, Ginger D. Regional distribution of cyclooxygenase- 2 in the hal formation in Alzheimer's disease. J Neurosci Res 1999; 57: 295-303.
112. Pasinetti GM. Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. J Neurosci Res 1998; 54: 1-6.
113. Munoz DG, Feldman H. Causes of Alzheimer's disease. Can Med Assoc J 2000; 162: 65-72.
114. Aisen PS, Davis KL, Berg JD. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000; 54: 588-593.
115. In t' Veld BA, Ruitenberg A, Hofman A. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-1521.
116. Licastro F, Chiappelli M. Brain immune responses cognitive decline and dementia: relationship with phenotype expression and genetic background. Mech Ageing Dev 2003; 124: 525-28.
117. Licastro F, Grimaldi LM, Bonafe M, et al. Interleukin-6 gene al leles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol Aging 2003; 24: 921-26.
118. Candore G, Balistreri CR, Colonna-Romano G, Lio D, Caruso C. Major histocompatibility complex and sporadic Alzheimer's disease: a critical reappraisal. Exp Gerontol 2004; 39: 645-52.
119. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-421.
120. Scola L, Licastro F, Chiappelli M, et al. Allele frequencies of +874T - > A single nucleotide polymorphism at the first intron of IFN-gamma gene in Alzheimer's diseae patients. Aging Clin Exp Res 2003; 15: 292-95.
121. Lio D, Licastro F, Scola L, et al. Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease. Genes Immun 2003; 4: 234-38.
122. McGeer PL, McGeer EG, Polymorphisms in inflammatory genes and the risk of Alzheimer disease. Arch Neurol 2001; 58: 1790-92.
123. Licastro F, Candore G, Lio D, et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immunol Ageing 2005; 2: 8.